Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00222534
Status:
COMPLETED
Last Update Posted:
2014-01-20
First Post:
2005-09-14
Brief Title:
Acetazolamide for Respiratory Failure in Combination With Metabolic Alkalosis
Sponsor:
University of Oslo School of Pharmacy
Organization:
University of Oslo School of Pharmacy
Study Overview
Official Title:
Acetazolamide for Respiratory Failure in Combination With Metabolic Alkalosis
Status:
COMPLETED
Status Verified Date:
2014-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Respiratory failure is a common consequence of chronic obstructive pulmonary disease COPD A concurrent metabolic alkalosis may worsen the respiratory failure as a higher pH in blood and thus in cerebrospinal fluid results in a weaker respiratory drive Use of diuretics is the most common cause of metabolic alkalosis
When a patient with an acute exacerbation of a respiratory failure is also alkalotic there are at least theoretical reasons to lower the pH in order to increase the respiratory drive Among other alternatives the drug acetazolamide can be used for this purpose
In some hospitals there is a tradition for the use of acetazolamide on this indication but any evidence for the effect of such a treatment is rather weak
Thus the aim of this trial is to evaluate the effect of acetazolamide as an adjuvant treatment for hospitalized patients with acute exacerbation of respiratory failure in combination with metabolic alkalosis
When a patient with an acute exacerbation of a respiratory failure is also alkalotic there are at least theoretical reasons to lower the pH in order to increase the respiratory drive Among other alternatives the drug acetazolamide can be used for this purpose
In some hospitals there is a tradition for the use of acetazolamide on this indication but any evidence for the effect of such a treatment is rather weak
Thus the aim of this trial is to evaluate the effect of acetazolamide as an adjuvant treatment for hospitalized patients with acute exacerbation of respiratory failure in combination with metabolic alkalosis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None